glp 1 for people not overweight Are YOU a Slow/Non-Responder to GLP-1's? GLP-1s have, I know, been

Healthcare providers recommend weekly blood pressure monitoring during the first month of combination therapy, with special attention during Mounjaro dose escalation periods

1 2 Calanna S, Christensen M, Holst JJ, Laferrre B, Gluud LL, Vilsbll T, Knop FK (May 2013)

However, CMS clarified in a memo dated March 20, 2024, that anti-obesity medications that receive FDA approval for an additional medically accepted indication can be considered a Part D drug for that specific use. As of August 19, 2024, the only GLP-1 RA this applies to is Wegovy, which, in addition to its obesity indication, is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight

10.1016/j.neuron.2019.05.035 241 KimS.-Y.WooS.-Y.RazaS.HoD.JeonS